275 related articles for article (PubMed ID: 12879454)
21. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways.
Nagy ZS; Wang Y; Erwin-Cohen RA; Aradi J; Monia B; Wang LH; Stepkowski SM; Rui H; Kirken RA
J Leukoc Biol; 2002 Oct; 72(4):819-28. PubMed ID: 12377952
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Miething C; Mugler C; Grundler R; Hoepfl J; Bai RY; Peschel C; Duyster J
Leukemia; 2003 Sep; 17(9):1695-9. PubMed ID: 12970766
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
27. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
28. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
29. [Effect on bcr-abl signaling pathway and the mechanisms of apoptosis induction by meisoindigo in K562 cells].
Liu BC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):815-8. PubMed ID: 19176035
[TBL] [Abstract][Full Text] [Related]
30. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
Carlesso N; Frank DA; Griffin JD
J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
Tauchi T; Nakajima A; Sashida G; Shimamoto T; Ohyashiki JH; Abe K; Yamamoto K; Ohyashiki K
Clin Cancer Res; 2002 Nov; 8(11):3341-7. PubMed ID: 12429620
[TBL] [Abstract][Full Text] [Related]
32. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
33. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats.
Frank DA; Varticovski L
Leukemia; 1996 Nov; 10(11):1724-30. PubMed ID: 8892675
[TBL] [Abstract][Full Text] [Related]
34. Association of CrkL with STAT5 in hematopoietic cells stimulated by granulocyte-macrophage colony-stimulating factor or erythropoietin.
Ota J; Kimura F; Sato K; Wakimoto N; Nakamura Y; Nagata N; Suzu S; Yamada M; Shimamura S; Motoyoshi K
Biochem Biophys Res Commun; 1998 Nov; 252(3):779-86. PubMed ID: 9837784
[TBL] [Abstract][Full Text] [Related]
35. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
37. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
[TBL] [Abstract][Full Text] [Related]
38. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
39. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
40. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells.
de Groot RP; Raaijmakers JA; Lammers JW; Koenderman L
Mol Cell Biol Res Commun; 2000 May; 3(5):299-305. PubMed ID: 10964754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]